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CASE REPORT
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Vandetanib is a once-daily oral anticancer drug that selec-
tively inhibits key signaling pathways in cancer by targeting 
vascular endothelial growth factor receptors, epidermal 
growth factor receptors  tyrosine kinase, and rearranged dur-
ing transfection-dependent tumor cell proliferation and sur-
vival. The most frequently reported adverse events attri-
buted to vandetanib include diarrhea, elevated aminotran-
sferase, asymptomatic corrected QT interval prolongation, 
and hypertension. Though a number of randomized, double- 
blind studies, including cutaneous adverse events attributed 
to vandetanib, have been reported along with these general 
symptoms, no case of Stevens-Johnson syndrome (SJS) has 
been reported. This paper demonstrates a case of SJS induced 
by vandetanib. (Ann Dermatol 23(S3) S343∼S345, 2011)
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INTRODUCTION
Vandetanib (Zactima
Ⓡ, AstraZeneca Pharmaceuticals, Lon-
don, UK) is an oral anticancer drug, used alone or com-
bined with doxetacel that has demonstrated a significant 
prolongation of progression-free survival in non-small-cell 
lung carcinoma (NSCLC). Although Phase I clinical evalu-
ation in patients with solid tumors showed that vandetanib 
monotherapy (up to 300 mg/d) was generally well toler-
ated, concerns have been expressed over the safety of 
vandetanib
1. Based on randomized Phase II clinical trials, 
the common vandetanib-related toxicities have been 
known to be as diverse as from dyspnea, possibly related 
to comorbid illness, to "rash"
2,3. These cutaneous events 
have been reported to have mild to moderate severity; a 
few patients developed skin eruptions of toxicity grade 3
2. 
Currently, no case of life-threatening cutaneous eruption 
such as Stevens-Johnson syndrome (SJS) induced by van-
detanib has been reported domestically or overseas.
CASE REPORT
 
 A 71-year old man was referred for consultation of diffuse 
erythematous targetoid maculopatches mainly on the face, 
neck and upper extremities. The patient had a history of 
non-small-cell lung carcinoma from July 2009. He had 
been treated with vandetanib at a dose of 300 mg daily. On 
day 21 of vandetanib treatment, he presented with multiple 
erythematous maculopatches, mainly on the face and neck. 
Five days later he exhibited multiple purpuric coalescing 
macules and vesicles on face and neck (Fig. 1). Diffuse 
erosion of oral mucosa and purpuric macules with flat 
atypical targets were observed on the face, palms (Fig. 2), 
soles, and trunk. Epidermal detachment developed appro-
ximately above 15 percent of the patient's body surface 
area. He had a body temperature of 38.3
oC, and com-
plained of odynophagia and conjunctivitis. Routine labo-
ratory examinations revealed leukocytosis (17,500/mm
3, 
NL (normal limit): 3,600∼10,200/mm
3), elevated eosino-
phil levels (11.4 IU/L, NL: 0∼8.2 IU/L), and abnormal 
alanine aminotransferase (ALT, 53 IU/L, NL: 0∼41 IU/L). 
Bacterial cultures from blood, urine, and sputum revealed 
no evidence of bacterial infection. Histopathologic find-
ings of biopsy on the patient's right forearm showed 
diffuse epidermal necrosis, including necrotic keratino-J Yoon, et al
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Fig. 3. Histopathologic findings of biopsy on his right forearm
showed diffuse epidermal necrosis including necrotic kerati-
nocytes and severe perivacular infiltration of lymphocytes (H&E,
×100).
Fig. 2. Multiple purpuric targetoid macules on the both palms
were observed.
Fig. 1. The patient exhibited multiple purpuric coalescing 
macules and vesicles on face and neck.
cytes, eosinophils, and severe perivacular infiltration of 
lymphocytes (Fig. 3). Considering that overall lesions 
showed violaceous targetoid macules, vesicular lesions 
diffusely developed on his whole body including extremi-
ties, palms, soles, trunk, oral mucosa, and conjunctiva, 
and skin biopsy showed epidermal necrosis and deta-
chment, these lesions were diagnosed as vandetanib- 
induced SJS. We recommended his oncologist to discon-
tinue the administration of the drug immediately. The skin 
lesions gradually resolved for 15 days after withdrawal of 
vandetanib, followed by antihistamines, topical corticos-
teroid, and wet dressing. The patch or provocation test 
could not be performed for safety reasons though it was 
needed for confirmation of the diagnosis. However, the 
patient had no history of taking any medication other than 
vandetanib, and no history of recurrent herpes simplex 
virus, mycoplasma pneumonia or other infections which 
were firmly established as the major causes of erythema 
multiforme. Considering that no proof of bacterial infec-
tion was observed in his blood, urine and sputum, we 
came to the conclusion that vandetanib had played a 
decisive role in his illness. There was no recurrence when 
he was followed up in three months.
DISCUSSION
SJS is an acute life-threatening muco-cutaneous disease 
characterized by extensive necrosis and detachment of the 
epidermis
4. According to Bastuji-Garin et al., consensus 
classification was proposed as: bullous erythema multifor-
me, detachment below 10 percent of the body surface area 
plus localized "typical targets" or "raised atypical targets"; 
SJS, detachment above 10 percent of the body surface 
area plus widespread erythematous or purpuric macules 
or flat atypical targets
5. The overall incidence of SJS was 
estimated at about one or two cases per million person- 
years
4. More than 100 different drugs have been reported 
as possible causes of SJS, including primarily allopurinol, 
sulfonamides, barbiturates, lamotrigine, phenytoin, oxicam 
non-steroidal anti-inflammatory agents (NSAIDs), and ami-
nopenicillin
4. The precise sequence of molecular and 
cellular events of SJS is not completely understood. How-
ever, the immunologic pattern of early lesions suggests a 
cell mediated cytotoxic reaction against keratinocytes, 
leading to massive apoptosis
4. 
Along with common adverse effects such as headache, 
nausea, diarrhea, constipation, abdominal distention/bl-
oating, elevated aspartate transaminase/alanine transami-Stevens-Johnson Syndrome Induced by Vandetanib
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nase and hypomagnesemia, the common cutaneous ad-
verse events attributed to vandetanib have been reported 
as acneiform rash, photosensitivity, alopecia and hand- 
foot syndrome
6. Horti et al. reported common adverse 
events that were related to vandetanib, including erythe-
matous rash (14 percent), and severe exfoliative rash (12 
percent) in their randomized, controlled study
2. According 
to another randomized double-blind controlled study, 
patients developed grade three skin desquamation, which 
meant a severe or medically significant condition requi-
ring hospitalization, but not immediately life-threatening. 
Recent clinical trials revealed that vandetanib has been 
linked to serious adverse events higher than grade three in 
approximately 55 percent of patients who used the me-
dication
7. The Food and Drug Administration Briefing 
Document Oncologic Drugs Advisory Committee Meeting 
in December, 2010 reported severe adverse events of 
vandetanib and is now asking an expert panel to discuss 
the medication and determine whether the "substantial 
toxicity" of vandetanib means that the drug should have 
limited indications
8. This toxicity includes ischemic 
arterial events, interstitial lung disease, and SJS. SJS and 
toxic epidermal necrolysis were reported in 0.7 percent of 
cases according to “significant adverse events” in the 
vandetanib safety database
8. Risk factors for evolution of 
rash into SJS are unclear, with eight of 21 patients 
receiving radiation prior to development of SJS
8. 
For SJS, Mockenhaupt et al.
9 classified marketed drugs as 
“highly suspected” drugs, namely anti-infective sulfona-
mides, anticonvulsants, oxicam-NSAIDs, and nonnucl-
eoside anti-retroviral agent, the anticonvulsant lamotri-
gine, “significant but lower risk” drugs such as NSAIDs, 
macrolides, and cephalosporins, “non-significant risk” 
drugs such as fluoxetine, other serotonin reuptake inhi-
bitors, proton pump inhibitors, 3-hydroxy-3-methylgluta-
ryl-coenzyme A (HMG-CoA) reductase, and “not asses-
sable” drugs such as terbinafine, fluconazole, and cycloo-
xygenase 2 inhibitors. As Vandetanib is still an experi-
mental drug, it has not been classified or verified in view 
of risk of SJS. Though clinical trials have revealed subs-
tantial risk posed by vandetanib, SJS attributed to this drug 
has not been presented as a case report or specifically 
evaluated in sufficient numbers of randomized controlled 
studies.
Physicians ought to consider the possibilities of drug 
hypersensitivity such as SJS as seen in our case, often 
leading to fatal outcomes, though the safety or tolerability 
of vandetanib has not been established. Clinical trials on 
vandetanib are currently underway upon the effectiveness 
of treating a variety of tumors, safe dosage, and adverse 
events attributed to it. Though vandetanib-induced drug 
eruption has not been frequently reported as of yet, the 
occurrence of adverse events attributed to the drug as 
shown above suggests discreet prescription of vandetanib 
and setting up of mandatory education of cutaneous 
adverse events induced by the drug would be beneficial.
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